The CRC cell models employed in our studies have KRAS (or BRAF) mutations [24], [45] and/or activated epidermal growth factor receptor (EGFR) pathways [58] , but they express comparatively low levels of EMT markers (ie, Snail1/2, Twist, and FOXC2 [59]), and their morphological features are indicative of an epithelial nature [59]. The gene discussed is KRAS; the disease is colorectal carcinoma.